Skip to main content

Anixa Biosciences Inc

ANIX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000715446

In the last 90 days, Anixa Biosciences Inc insiders filed 15 open-market purchases and 0 sales; 63 institutions reported holding it in 13F filings for Q2 2026, worth $15.0M in total; no superinvestor holds it.

Q2 2023 vs. Q1 2023

How the institutions holding Anixa Biosciences Inc changed between Q1 2023 and Q2 2023.

All holders in Q2 2023All holders in Q1 2023

13F holders of ANIX: Q1 2023 compared with Q2 2023
MeasureQ1 2023Q2 2023Change
Holders4445+1
Shares3.66M3.65M−17.2K (−0.5%)
Value$15.8M$11.7M−$4.08M (−25.9%)

New holders (6)

Institutions that held Anixa Biosciences Inc at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to ANIX in Q2 2023
InstitutionSharesValue% of portfolio
Tyler-Stone Wealth Management21,008$67.0K0.04%
Concorde Asset Management, LLC15,481$49.5K0.05%
Westside Investment Management, Inc.13,800$44.2K0.01%
Commonwealth Equity Services, LLC10,571$34.0K0.00%
Group One Trading, L.P.5,970$19.1K0.00%
Signaturefd, LLC57$1820.00%

Sold out (5)

Institutions that held Anixa Biosciences Inc at the end of Q1 2023 and filed for Q2 2023 without it.

Institutions that sold out of ANIX in Q2 2023
InstitutionShares, Q1 2023Value, Q1 2023
Jane Street Group, LLC61,810$265.8K
Virtu Financial LLC18,409$79.0K
Simplex Trading, LLC16,962$72.0K
National Asset Management, Inc.15,200$65.4K
Advisory Services Network, LLC674$2.90K